Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy

Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy

Abstract Background Ductal adenocarcinoma of the pancreas (PDAC) remains one of the most lethal malignancies. To date, no guidelines exists for isolated resectable metachronous disease. It is still unknown, which patients may benefit from relapse surgery. The aim of our study was to compare disease...

Full description

Bibliographic Details
Main Authors: S. A. Safi, N. Lehwald-Tywuschik, A. Rehders, G. Fluegen, L. Haeberle, V. Keitel, W. T. Knoefel
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Surgery
Subjects:
PDAC
Ductal adenocarcinoma of the pancreas
Oligometastatic
Survival outcome
Pulmonary metastases
Local recurrence
Online Access:https://doi.org/10.1186/s12893-021-01082-w

Internet

https://doi.org/10.1186/s12893-021-01082-w

Similar Items